Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

News Daily News

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

December 23, 2020

Inclisiran Approved in Europe for Lowering LDL Cholesterol

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

News Daily News

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Michael O'Riordan

December 07, 2020

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

News Conference News AHA 2020

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

November 18, 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

News Conference News AHA 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Michael O'Riordan

November 15, 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

News Conference News AHA 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

November 15, 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

November 15, 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

October 21, 2020

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

News Daily News

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

August 03, 2020

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

News Daily News

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

May 28, 2020

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.